Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia : an open-label, multicentre, randomised, controlled trial

Hagman, Karl ; Hedenstierna, Magnus ; Andersson Norlén, Elina ; Biasoletto, Karin ; Eklund Josephson, Maria ; Fraenkel, Carl Johan LU orcid ; Hedman, Elin ; Ljungberg, Johan ; Ljungquist, Oskar LU and Månsson, Viktor LU , et al. (2026) In The Lancet Regional Health - Europe 64. p.1-10
Abstract

Background: Adjunctive corticosteroid therapy appears to be beneficial for adults with severe community-acquired pneumonia (CAP), but data on Mycoplasma pneumoniae CAP are limited. This study aimed to evaluate if adjunctive betamethasone reduced time to resolution of hypoxaemia in adults hospitalised with M. pneumoniae CAP. Methods: An open-label, multicentre, randomised, controlled trial was conducted at eight Swedish hospitals. Adults admitted with M. pneumoniae CAP and hypoxaemia (SpO2 <93% and respiratory rate >20 breaths/min) were eligible. Exclusion criteria included asthma and diabetes mellitus. Participants were randomised (1:1) to either standard care without corticosteroids or adjunctive oral betamethasone (3... (More)

Background: Adjunctive corticosteroid therapy appears to be beneficial for adults with severe community-acquired pneumonia (CAP), but data on Mycoplasma pneumoniae CAP are limited. This study aimed to evaluate if adjunctive betamethasone reduced time to resolution of hypoxaemia in adults hospitalised with M. pneumoniae CAP. Methods: An open-label, multicentre, randomised, controlled trial was conducted at eight Swedish hospitals. Adults admitted with M. pneumoniae CAP and hypoxaemia (SpO2 <93% and respiratory rate >20 breaths/min) were eligible. Exclusion criteria included asthma and diabetes mellitus. Participants were randomised (1:1) to either standard care without corticosteroids or adjunctive oral betamethasone (3 mg daily on days 1–2, and 2 mg daily on days 3–5). Antibiotic treatment was standardised to 200 mg doxycycline once daily for 10 days. The primary outcome was time to resolution of hypoxaemia in an intention-to-treat analysis. Safety was assessed in participants receiving at least one betamethasone dose. The study was registered with the EU Clinical Trials Register (EudraCT 2016-002585-32) and is completed. Findings: Between March 1, 2018, and November 14, 2024, 70 participants were enrolled: 36 in the betamethasone group and 34 in the control group. The median age was 42 years (IQR 28–49) including 40 (57%) male and 30 (43%) female participants. All participants achieved resolution of hypoxaemia except two who withdrew consent. Time to resolution of hypoxaemia was shorter in the betamethasone group (HR 1.82 [95% CI 1.10–3.02], p = 0.020) compared to the standard of care group, with an estimated median of 2.3 (95% CI 1.8–2.7) and 3.6 (95% CI 1.9–5.3) days, respectively. Adverse events were similar between study groups. Severe adverse events were rare, and none were attributed to betamethasone treatment. Interpretation: Adjunctive betamethasone was well tolerated and significantly shortened the duration of hypoxaemia in adults hospitalised with M. pneumoniae CAP in this open-label trial. Funding: The Swedish Society of Medicine.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antibiotics, Atypical pneumonia, Corticosteroids, Doxycycline, Oxygen
in
The Lancet Regional Health - Europe
volume
64
article number
101610
pages
1 - 10
publisher
Elsevier
external identifiers
  • pmid:42099880
  • scopus:105044246831
ISSN
2666-7762
DOI
10.1016/j.lanepe.2026.101610
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2026 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/
id
830ee9f8-e1d2-404c-a474-782d8d412982
date added to LUP
2026-09-22 14:55:43
date last changed
2026-09-24 03:15:26
@article{830ee9f8-e1d2-404c-a474-782d8d412982,
  abstract     = {{<p>Background: Adjunctive corticosteroid therapy appears to be beneficial for adults with severe community-acquired pneumonia (CAP), but data on Mycoplasma pneumoniae CAP are limited. This study aimed to evaluate if adjunctive betamethasone reduced time to resolution of hypoxaemia in adults hospitalised with M. pneumoniae CAP. Methods: An open-label, multicentre, randomised, controlled trial was conducted at eight Swedish hospitals. Adults admitted with M. pneumoniae CAP and hypoxaemia (SpO<sub>2</sub> &lt;93% and respiratory rate &gt;20 breaths/min) were eligible. Exclusion criteria included asthma and diabetes mellitus. Participants were randomised (1:1) to either standard care without corticosteroids or adjunctive oral betamethasone (3 mg daily on days 1–2, and 2 mg daily on days 3–5). Antibiotic treatment was standardised to 200 mg doxycycline once daily for 10 days. The primary outcome was time to resolution of hypoxaemia in an intention-to-treat analysis. Safety was assessed in participants receiving at least one betamethasone dose. The study was registered with the EU Clinical Trials Register (EudraCT 2016-002585-32) and is completed. Findings: Between March 1, 2018, and November 14, 2024, 70 participants were enrolled: 36 in the betamethasone group and 34 in the control group. The median age was 42 years (IQR 28–49) including 40 (57%) male and 30 (43%) female participants. All participants achieved resolution of hypoxaemia except two who withdrew consent. Time to resolution of hypoxaemia was shorter in the betamethasone group (HR 1.82 [95% CI 1.10–3.02], p = 0.020) compared to the standard of care group, with an estimated median of 2.3 (95% CI 1.8–2.7) and 3.6 (95% CI 1.9–5.3) days, respectively. Adverse events were similar between study groups. Severe adverse events were rare, and none were attributed to betamethasone treatment. Interpretation: Adjunctive betamethasone was well tolerated and significantly shortened the duration of hypoxaemia in adults hospitalised with M. pneumoniae CAP in this open-label trial. Funding: The Swedish Society of Medicine.</p>}},
  author       = {{Hagman, Karl and Hedenstierna, Magnus and Andersson Norlén, Elina and Biasoletto, Karin and Eklund Josephson, Maria and Fraenkel, Carl Johan and Hedman, Elin and Ljungberg, Johan and Ljungquist, Oskar and Månsson, Viktor and Nygren, David and de Oliveira e Costa, Milena and Rydén, Cecilia and Skov Jensen, Jørgen and Stenlund, Göran and Tverring, Jonas and Wasserstrom, Lisa and Nilsson, Anna C. and Ursing, Johan}},
  issn         = {{2666-7762}},
  keywords     = {{Antibiotics; Atypical pneumonia; Corticosteroids; Doxycycline; Oxygen}},
  language     = {{eng}},
  pages        = {{1--10}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet Regional Health - Europe}},
  title        = {{Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia : an open-label, multicentre, randomised, controlled trial}},
  url          = {{http://dx.doi.org/10.1016/j.lanepe.2026.101610}},
  doi          = {{10.1016/j.lanepe.2026.101610}},
  volume       = {{64}},
  year         = {{2026}},
}